1 / 12

Supply of OPV by M/s RITES

Supply of OPV by M/s RITES. Twenty Fourth Meeting Of the India Expert Advisory Group (IEAG) for Polio Eradication on 15 th March 2012. By S N Panda GM/Rites. Outline of Presentation. Introduction Procurement Objective Supply overview Our Experience Recommendation.

briar-thomas
Télécharger la présentation

Supply of OPV by M/s RITES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supply of OPV by M/s RITES Twenty Fourth Meeting Of the India Expert Advisory Group (IEAG) for Polio Eradication on 15th March 2012 By S N Panda GM/Rites

  2. Outline of Presentation • Introduction • Procurement Objective • Supply overview • Our Experience • Recommendation

  3. Introduction • M/s RITES Limited(A PSU under Ministry of Rlys) assisting the Department of Health & Family Welfare as Procurement Agent for procurement of OPVs funded by External Agencies like World Bank since May’ 2010 previously handled by UNICEF • In FY 2010-11 five indents were processed for four types of vaccines like bOPV, tOPV,mOPV1 and mOPV3 • In FY 2011-12 two indents were processed for two types of vaccines like bOPV and tOPV only • In FY 2012-13 one indent is already processed for bOPV (Supply in April – June 2012)

  4. Vaccine Supply Objectives To ensure a sustained and uninterrupted supply of quality vaccines Through • WHO Prequalification • Appropriate contracting

  5. Supply of OPV *One of the bidder’s manufacturing process was taken on review by WHO during decision process

  6. Response From Suppliers in 2011-12

  7. Installed Capacity of OPV Suppliers (Participated in RITES Tender)

  8. Our OPV Procurement Experience • 50% of qualified suppliers participated in Bid • Mostly suppliers from India participated though it was a LIB except M/s Sanofi from France • No offer for full Bid quantity • Appreciable gap in offered price of different suppliers

  9. Reasons for low response • Demand- Supply gap • Shortage of bulk in International market • Non participation of foreign suppliers due to (i) supply of OPV in short notice (ii) shelf life of minimum 18 months on the date of arrival at port of entry in India (iii) Marking of “CGS Not for Sale” on primary packaging

  10. OPV Requirement for 2012-13 rounds

  11. Recommendation of RITES • Indent should be sent at least 12 months in advance with respect to supply requirement so that tender can be finalised six months prior to requirements. This implies advanced planning and long term IEAG recommendations. • Residual Shelf Life of vaccine at the time of supply as per Indian Drug & Cosmetic Act (i.e. 60% of total life of 24 months) instead of 18 months • Waiver of “CGS Not for Sale” on primary packaging

  12. Thank You

More Related